Understanding immune response in sepsis and septic shock
Immune Homeostasis in Patients With Sepsis and Septic Shock: a Single Center Observational Study
This study looks at how the immune system reacts in people with sepsis and septic shock to see if understanding these responses can help improve treatment in the future.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Charles University, Czech Republic Academic / other |
| Locations | 1 site (Pilsen, Česká Republika) |
| Trial ID | NCT04448951 on ClinicalTrials.gov |
What this trial studies
This observational study aims to explore the dynamics of the immune response in patients suffering from sepsis and septic shock. Utilizing advanced techniques such as transcriptomics, flow-cytometry, and cytokine analysis, the study seeks to provide a detailed characterization of immune homeostasis in these critical conditions. By examining the immune profiles of patients within the first 24 hours of diagnosis, the research intends to uncover insights that could inform future therapeutic strategies.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older who have been diagnosed with sepsis or septic shock within the first 24 hours.
Not a fit: Patients with primary or secondary immunodeficiency or active malignancies may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and management of immune dysfunction in sepsis, potentially enhancing patient outcomes.
How similar studies have performed: While the specific approach of this study may be novel, previous studies have indicated the importance of understanding immune responses in sepsis, suggesting potential for meaningful insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * sepsis/septic shock (SEPSIS-3) * age ≥18 * informed consent * inclusion within first 24hrs after development/diagnosis of septic shock Exclusion Criteria: * disagreement of the patient or legal representative with the entry into the study * patients with primary or secondary immunodeficiency * presence of active haematological malignancy or an active non-haematological malignancy
Where this trial is running
Pilsen, Česká Republika
- Medical ICU, 1st Dept. of Internal Medicine, Teaching Hospital in Pilsen — Pilsen, Česká Republika, Czechia (Recruiting)
Study contacts
- Principal investigator: Thomas Karvunidis, MD, PhD — Carles University Teaching Hospital and Faculty of Medicine in Pilsen, Pilsen, Czech Republic
- Study coordinator: Thomas Karvunidis, MD, Ph.D.
- Email: karvunidist@fnplzen.cz
- Phone: +420 377 103 173
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.